Efficacy and safety of dostarlimab in UK-specific patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) or DNA polymerase epsilon, catalytic subunit (POLε)-mutated solid tumours in the GARNET study

被引：1

作者：

Samuel, L.

Miller, R.

Ross, P.

Arkenau, T. ^{[1
]}

Antony, G. ^{[2
]}

Veneris, J.

Rule, J. ^{[2
]}

Starling, N. ^{[3
]}

机构：

[1] Sarah Cannon Res Inst, London, England

[2] GlaxoSmithKline, London, England

[3] Royal Marsden, London, England

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

基金：

芬兰科学院;

关键词：

D O I：

10.1016/j.annonc.2023.04.220

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-164

引用

页码：S73 / S74

页数：2

共 50 条

[41] Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study [J].

Vogel, A. ;

Hanker, L. ;

Andre, T. ;

Berton, D. ;

Curigliano, G. ;

Ellard, S. L. ;

Trigo, J. ;

Arkenau, H. -T ;

Abdeddaim, C. ;

Moreno, V ;

Guo, W. ;

Im, E. ;

Starling, N. .

ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 :82-82

[42] Combination of nivolumab (nivo) plus ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study. [J].

Andre, Thierry ;

Lonardi, Sara ;

Wong, Ka Yeung Mark ;

Morse, Michael ;

McDermott, Raymond S. ;

Hill, Andrew Graham ;

Hendlisz, Alain ;

Lenz, Heinz-Josef ;

Leach, Joseph W. ;

Moss, Rebecca Anne ;

Cao, Z. Alexander ;

Ledeine, Jean-Marie ;

Chan, Emily ;

Kopetz, Scott ;

Michael, J. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[43] Iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors: A single-arm, multicenter, pivotal, phase II study [J].

Guo, Weijian ;

Bi, Feng ;

Dong, Jian ;

Jin, Chuan ;

Niu, Zuoxing ;

Wang, Yusheng ;

Sun, Meili ;

Wang, Teng ;

Yu, Dajun ;

He, Yifu ;

Zhang, Ruixing ;

Yin, Xianli ;

Feng, Wenlei ;

Zhang, Meijiang ;

Zhang, Baihui ;

Li, Lingyan ;

Kang, Xiaoyan .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[44] Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study. [J].

Andre, Thierry ;

Berton, Dominique ;

Curigliano, Giuseppe ;

Ellard, Susan ;

Trigo Perez, Jose Manuel ;

Arkenau, Hendrik-Tobias ;

Abdeddaim, Cyril ;

Moreno, Victor ;

Guo, Wei ;

Im, Ellie ;

Starling, Naureen .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)

[45] Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors [J].

Li, J. ;

Xu, Y. ;

Zang, A. ;

Gao, Y. ;

Gao, Q. ;

Zhang, Y. ;

Wang, D. ;

Xu, J. ;

Yuan, Y. ;

Jiang, H. ;

Ying, J. ;

Shi, C. ;

Deng, Y. ;

Wang, J. ;

Liu, T. ;

Huang, Y. ;

Shi, M. ;

Wang, K. ;

Hu, H. ;

Shen, L. .

ANNALS OF ONCOLOGY, 2023, 34 :S640-S640

[46] MyTACTIC: Afficacy and safety of atezolizumab (atezo) plus chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR) [J].

Spigel, David R. ;

Hussein, Maen A. ;

Zuniga, Richard ;

Mahadevan, Daruka ;

Winn, Robert ;

Darbonne, Walter C. ;

Yoo, Bongin ;

Kim, Young ;

Whitehead, Zach ;

Vanderwalde, Ari M. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[47] A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW [J].

Andre, T. ;

Van Cutsem, E. ;

Elez, E. ;

Bennouna, J. ;

de la Fouchardiere, C. ;

Yoshino, T. ;

Jensen, L. ;

Mendez, G. ;

Li, J. ;

Goekkurt, E. ;

Abdullaev, S. ;

Chen, T. ;

Lei, M. ;

Lonardi, S. .

ANNALS OF ONCOLOGY, 2022, 33 :S250-S250

[48] Molecular and immune landscape by cyclin dependent kinase (CDK) 4/6 expression and TP53 mutational status in mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC). [J].

Wong, Alexandra ;

Gandhi, Nishant ;

Xiu, Joanne ;

Algaze, Sandra ;

Jayachandran, Priya ;

Ashouri, Karam ;

Soni, Shivani ;

Zhang, Wu ;

Lo, Jae Ho ;

Mittal, Pooja ;

Torres-Gonzalez, Lesly ;

Weinberg, Benjamin Adam ;

Lou, Emil ;

Goel, Sanjay ;

Yu, Jian ;

Zhang, Lin ;

Battaglin, Francesca ;

Lenz, Heinz-Josef .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) :190-190

[49] Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H) [J].

Liao, Ying ;

Zhu, Changhua ;

Song, Xiaoxia ;

Ruan, Jiugen ;

Ding, Yao ;

Chen, Yuan ;

Yang, Qiujuan .

MEDICAL SCIENCE MONITOR, 2022, 28

[50] Impact of BRAF-V600E mutation on immunologic characteristics of the tumor microenvironment (TME) and associated genomic alterations in patients with microsatellite instability-high (MSI-H) or mismatch-repair-deficient (dMMR) colorectal cancer (CRC) [J].

Salem, M. ;

Kopetz, S. ;

El-Refai, S. ;

Tabernero, J. ;

Sinicrope, F. ;

Tie, J. ;

George, T. ;

Van Cutsem, E. ;

Mauer, E. ;

Lonardi, S. ;

Andre, T. ;

Overman, M. ;

Foureau, D. .

ANNALS OF ONCOLOGY, 2022, 33 :S378-S378

← 1 2 3 4 5 →